ABSTRACT
A vacina anti-diftérica de uso corrente no Brasil (DTP), embora de alta eficácia na prevenção da difteria, está associada com episódios de toxicidade e reatogenicidade no recipiente vacinal, resultantes de proteínas residuais derivadas do processo de produção ou detoxificação. Estratégias para o desenvolvimento de vacinas menos reatogênicas e ao mesmo tempo mais eficazes e economicamente viáveis contra a difteria têm sido alvo de intensa investigação. A alternativa proposta por nosso grupo é a utilização da vacina contra a tuberculose (Mycobacterium bovis BCG sub-cepa Moreau), como vetor do gene que codifica o fragmento B da toxina diftérica (dtb) de 58,3 kDa. Neste trabalho o dtb foi clonado no vetor micobacteriano bifuncional (pUS977) de expressão citoplasmática e os clones recombinantes (pUS977dtbPW8), após a transformação do BCG, foram testados com relação a expressão do DTB em BCG e quanto a antigenicidade frente a anticorpos policlonais anti-toxóide diftérico por Immunobloting. A integridade do gene dtb e a identidade das sequências de DNA da construção plasmidial pUS977dtbPW8 foram confirmadas por sequenciamento de DNA e análise de similaridade. A imunogenicidade do BCGr pUS977dtbPW8 expressando o DTB foi investigada em camundongos BALB/c, os resultados obtidos revelaram uma soroconversão específica (IgG). A infectividade e atividade microbicida do BCGr pUS977dtbPW8 no ambiente intracelular foi avaliada através da infecção de linhagens de células de monócitos humano (THP-1), os dados obtidos indicaram que houve sobrevivência intracelular em até 12 dias. Nesse contexto, esplenócitos dos camundongos imunizados com 30 e 60 dias foram extraídos, mostrando que o BCGr pUS977dtbPW8 persistiu até 60 dias na ausência de pressão seletiva e a viabilidade celular não sofreu alteração significativa durante o período testado...
The diphtheria vaccine currently used in Brazil (DTP), despite its history of high efficacy in the prevention of diphtheria, is associated with episodes of toxicity and vaccine reactogenicity in the vaccinee, resulting from the presence in the vaccine of residual proteins derived from the production process or detoxification. Strategies for the development of new vaccines more effective and economically viable against diphtheria have been the subject of intense investigation. The alternative proposed by our group is the use of the vaccine against tuberculosis (Mycobacterium bovis BCG Moreau sub strain) as a vector for the gene that encodes the 58.3 kDa fragment B of the diphtheria toxin (DTB). In our project the dtb gene was cloned into the bifunctional vector pUS977 for cytoplasmic expression and recombinant BCG (rBCG) clones, selected after transformation of BCG, were tested for expression of the DTB polypeptide and antigenicity against polyclonal antibodies anti- diphtheria toxoid by immunoblotting. The integrity and identity of the DNA sequence encoding the dtb gene carried by the plasmid construct pUS977dtbPW8 was confirmed by DNA Sequencing and Analysis of Similarity. The immunogenicity of the rBCG expressing the DTB was investigated in BALB/c mice and the results revealed a specific seroconversion (IgG)...
Subject(s)
Animals , Mice , BCG Vaccine , Corynebacterium diphtheriae/immunology , Mycobacterium bovis/immunology , Diphtheria Toxin/antagonists & inhibitors , Diphtheria-Tetanus-Pertussis Vaccine/immunology , Corynebacterium diphtheriae/genetics , Corynebacterium diphtheriae/virology , Genetic Engineering , Genetic Vectors , Mice, Inbred BALB C , Mycobacterium bovis/genetics , Diphtheria Toxin/toxicity , Vero CellsABSTRACT
Se evaluó el uso de la tecnología de Flujo de Filtración Tangencial (FFT), para obtener la toxina diftérica a partir de cultivos de la bacteria Corynebacterium diphtheriae, usando el proceso de Microfiltración (MF), para eliminar el paquete celular y posteriormente, a partir del filtrado obtenido, concentrar y diafiltrar la toxina diftérica usando el proceso de Ultrafiltración (UF). Se determinaron características de los filtros, condiciones de trabajo y dimensionamiento de los equipos a adquirir para la producción industrial de Toxina Diftérica. Se evaluaron el flujo, tiempo, rendimiento del proceso y las características del producto obtenido, utilizando cultivos con Toxina Diftérica en un equipo de filtración de laboratorio, diseñado para producir el efecto de FFT. Seseleccionó las membranas tipo cassettes, formato Médium Screen, porosidad 0,2 μm, como las adecuadas para el proceso de MF, ya que mostraron 100% de transmisión de la Toxina Diftérica, ausencia de restos celulares y flujo promedio de filtrado de 9.16 L/m2h. Así mismo, se seleccionaron las membranas tipo cassettes, formato Omega, porosidad 10 y 30 kDa, como las adecuadas para el proceso de UF, ya que mostraron 100% de recuperación de la toxina, ausencia de toxina en el filtrado y adecuados flujos de filtrado (97,5 y 125,9 L/m2h, respectivamente), Estos resultaron permitieron dimensionar, considerando las variables a utilizar en la producción industrial (Volumen 650 a 950 Litros, Tiempo de Procesos, 3 a 5 horas), el área de filtración de los equipos de MF y UF a adquirir, estimados en 20m2 y 5m2, respectivamente.
Tangential Flow Filtration (TFF) technology was evaluated to process diphtheria toxin which is produced by Cory ne - bacterium diphtheriae bacterium. Microfiltration (MF) is used to retain cells while allowing passage of the toxin to the filtrate stream. The filtrate is collected and further pro - cessed by Ultrafiltration (UF) to concentrate the toxin and to maximize the wash of small species by a Diafiltration step. Both, MF and UF processes were evaluated to specify the filters and corresponding critical process parameters to scale-up the application. As part of the evaluation, flow rate, processing time, yield and product attributes were characterized. The cell harvest containing the diphtheria toxin was processed using a laboratory scale TFF system designed to product the TFF effect. The evaluation demonstrated that a cassette in medium screen format and membrane with 0.2 μm pore is the right selection for the MF step. It showed 100% of toxin transmission without the presence of cellular debris and average process flux of 9.16 L/m2h. The UF step was conducted using the same laboratory equipment with cassettes in medium screen format with pores of 10 and 30 kD. It showed 100% retention of the toxin with a process flux of 97,5 and 125,9 L/m2h, respectively. These results were used to scale-up the application to process the industrial volume of 650 a 950 liters between 3 to 5 hours of processing time. Membrane area sizing of MF and UF to be acquired is estimated in 20 m2 and 5m2, respectively.
Subject(s)
Humans , Male , Female , Ultrafiltration/instrumentation , Cell Separation/methods , Microstraining/methods , Diphtheria Toxin/toxicity , Proteins/metabolism , Public HealthABSTRACT
Effect of monensin, intercalated in liposomes on the cytotoxicities of ricin, Pseudomonas exotoxin A and diphtheria toxin in phagocytic and non-phagocytic cells as well as in mice has been studied. Intercalation does not disturb the integrity of the liposomal bilayer and substantially enhances the cytotoxicities of ricin and Pseudomonas exotoxin A in both phagocytic and non-phagocytic cells while it has no effect on diphtheria toxin. The observed effect is highly dependent on the liposomal lipid composition as well as cell types. The potentiating ability of monensin in neutral vesicle is 2.2-fold higher than in negatively charged vesicles in non-phagocytic cells while no difference was observed in phagocytic cells. Incorporation of stearylamine in liposomes reduces the potentiating effect of monensin. Liposomal monensin has also been found to enhance the cytotoxicity of ricin in mouse in vivo in a dose-dependent manner and is maximal when ricin is injected within 60 min of monensin injection. Liposomal monensin remains in circulation for 2 hr while free monensin remains only for 15 min. Tissue distribution studies reveal that liposomal monensin is present mainly in the liver and spleen which are also the major sites for ricin accumulation. Thus liposome is found to be an effective delivery vehicle for monensin to potentiate the cytotoxicity of immunotoxins or hormonotoxins and could prove useful for selective elimination of cancer cells.
Subject(s)
ADP Ribose Transferases , Animals , Bacterial Toxins , CHO Cells , Cell Survival/drug effects , Cricetinae , Diphtheria Toxin/toxicity , Drug Carriers , Drug Synergism , Exotoxins/toxicity , Lipid Bilayers , Macrophages/cytology , Mice , Monensin/administration & dosage , Phagocytosis , Pseudomonas aeruginosa , Ricin/toxicity , Virulence FactorsABSTRACT
Para evaluar la eficacia preventiva de la DL-carnitina en el miocardio, se estudiaron 40 niños con difteria, internados en el Servicio de Infecto-contagiosas del Departamento de Pediatría, Hospital Belén, Trujillo-Perú entre 1986 a 1989. Veinte niños recibieron tratamiento estandar (grupo control) y los otros 20 tratamiento estandar + carnitina: 100 mg/k/d, dos dosis por día y por 4 días consecutivos. El compromiso miocárdico se determinó por la clínica, ECG, niveles de TSGO > 60 UK/ml (29 UI) y el promedio en días de estancia hospitalaria. Miocarditis se presentó en 75 por ciento del grupo control (sin carnitina) y en 30 por ciento del grupo experimental (con carnitina), p < 0.01; la estancia hospitalaria fue de 17.5 días en el primero y 10.8 en el segundo, p < 0.005; mientras por gravedad de miocarditis no fue significativo en ambos grupos. Se concluye, que la DL-carnitina oral asociado al tratamiento estandar de la difteria en niños, tiene efecto preventivo de miocarditis